Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...
Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in combination with nivolumab (CaboNivo) versus sunitinib in people living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback